Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.968
+0.108 (12.55%)
At close: Dec 20, 2024, 4:00 PM
1.040
+0.072 (7.45%)
After-hours: Dec 20, 2024, 7:53 PM EST
Palatin Technologies Revenue
Palatin Technologies had revenue of $2.38M in the twelve months ending September 30, 2024, down -60.85% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
$2.38M
Revenue Growth
-60.85%
P/S Ratio
6.75
Revenue / Employee
$79,470
Employees
30
Market Cap
18.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Concord Medical Services Holdings | 64.91M |
Flora Growth | 64.15M |
Retractable Technologies | 38.27M |
BioLineRx | 21.99M |
CervoMed | 10.07M |
Bolt Biotherapeutics | 9.78M |
Alterity Therapeutics | 2.68M |
PTN News
- 2 days ago - Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PRNewsWire
- 5 days ago - Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - PRNewsWire
- 26 days ago - Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PRNewsWire
- 5 weeks ago - Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 5 weeks ago - Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - PRNewsWire
- 6 weeks ago - Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - PRNewsWire
- 6 weeks ago - Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PRNewsWire
- 7 weeks ago - Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - PRNewsWire